表紙
市場調查報告書

再生醫療市場分析:產品,治療領域,地區別預測

Regenerative Medicine Market Size, Share & Trends Analysis By Product (Primary Cell-based, Stem & Progenitor Cell-based), By Therapeutic Category (Dermatology, Oncology) And Segment Forecasts, 2019 - 2025

出版商 Grand View Research, Inc. 商品編碼 544778
出版日期 內容資訊 英文 247 Pages
商品交期: 2-3個工作天內
價格
Back to Top
再生醫療市場分析:產品,治療領域,地區別預測 Regenerative Medicine Market Size, Share & Trends Analysis By Product (Primary Cell-based, Stem & Progenitor Cell-based), By Therapeutic Category (Dermatology, Oncology) And Segment Forecasts, 2019 - 2025
出版日期: 2019年06月19日內容資訊: 英文 247 Pages
簡介

本報告提供再生醫療的全球市場調查,提供整體市場趨勢,各產品·治療領域,地區別詳細趨勢,市場變化與預測,推動市場要素及阻礙因素分析,競爭環境,主要企業簡介等系統性資訊。

第1章 調查手法

第2章 摘要整理

第3章 再生醫療市場趨勢

  • 市場區隔·範圍
    • 推動市場要素
    • 市場阻礙因素
  • 市場滲透度·成長預測的製圖
  • SWOT分析
  • 波特的五力分析
  • 企業的開發平台分析
  • 法規環境
    • 美國
    • 加拿大
    • 歐洲
    • 日本
    • 中國

第4章 再生醫療市場分析:各產品

  • 市場趨勢分析:各產品
  • 治療方法
    • 第一代培養細胞法
    • 基幹細胞·前驅細胞療法
    • 免疫細胞療法
    • 基因治療
  • 醫療設備
  • 再生醫療銀行
  • 服務

第5章 再生醫療市場分析:各治療領域

  • 市場趨勢分析:各治療領域
  • 皮膚
  • 肌肉骨骼
  • 免疫·發炎
  • 癌症
  • 心血管
  • 其他

第6章 再生醫療市場分析:各地區

  • 各地區的市場佔有率
  • 北美
    • 北美的再生醫療市場:各產品
    • 北美的再生醫療市場:各治療領域
    • 美國的再生醫療市場
    • 加拿大的再生醫療市場
  • 歐洲
    • 歐洲的再生醫療市場:各產品
    • 歐洲的再生醫療市場:各治療領域
    • 德國的再生醫療市場
    • 英國的再生醫療市場
  • 亞太地區
    • 亞太地區的再生醫療市場:各產品
    • 亞太地區的再生醫療市場:各治療領域
    • 日本的再生醫療市場
    • 中國的再生醫療市場
  • 南美
    • 南美的再生醫療市場:各產品
    • 南美的再生醫療市場:各治療領域
    • 巴西的再生醫療市場
  • 中東·非洲
    • 中東·非洲的再生醫療市場:各產品
    • 中東·非洲的再生醫療市場:各治療領域
    • 南非的再生醫療市場

第7章 競爭環境

  • 策略的組成架構
  • 參與企業的區分
  • 企業簡介

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GVR-1-68038-952-4

The global regenerative medicine market size is expected to reach USD 5.60 billion by 2025, expanding at a CAGR of 11.6% over the forecast period, according to a new report by Grand View Research, Inc. Regenerative medicines are expected to have a significant impact in healthcare to treat specific indications and chronic conditions. Therefore, high prevalence of cancer, neurodegenerative, orthopedic, and other aging-associated disorders coupled with increasing global geriatric population is driving the market growth. Moreover, rising prevalence of inheritable genetic diseases is anticipated to fuel the demand in the field of biotechnology field.

Market players are engaged in implementing novel protocols for the release of novel therapeutics. For instance, in July 2018, Convelo Therapeutics launched regenerative medicines for the treatment of various neurological diseases, such as multiple sclerosis.Agreements models initiated by the companies coupled with commercialization in emerging countries fuels the growth. For instance, in March 2018, Hitachi Chemical signed an agreement with the Daiichi Sankyo and SanBio Group to conduct clinical manufacturing of regenerative medicines developed by respective companies for Japanese and U.S. markets.

Regenerative medicine is anticipated to witness great attention in healthcare sector due to its wide range of applications and significant advancements tissue engineering, stem cells, gene therapy, drug discovery, and nanotechnology. For example, 3D printing is preferred over scaffold with stem cells to restore structure and functional characteristics of biological specimens.

Dermatology is estimated to hold the largest market share in terms of revenue in 2018, owing to the availability of various products and their application in simple and chronic wound healing. Oncology therapeutic category on the other hand, is projected to expand at the fastest CAGR during the forecast period owing to the presence of strong pipeline of regenerative medicines for cancer treatment.

North America held the largest regenerative medicine market share in terms of revenue in 2018 and is projected to continue its dominance in near future. A significant number of universities and research organizations investigating various stem cell-based approaches for regenerative apposition in U.S. is anticipated to propel the growth.

Further key findings from the report suggest:

  • Therapeutics emerged dominant among product segments in 2018 due to high usage of primary cell-based therapies along with advances in stem cell and progenitor cell therapies
  • Implementation of primary cell-based therapies in dermatological, musculoskeletal, and dental application results in highest share of this segment
  • Stem cell and progenitor cell-based therapies are anticipated to witness rapid growth due to high investments in stem cell research and increasing number of stem cell banks
  • With rise in R&D and clinical trials, key players are offering consulting services leading to lucrative growth of the services segment
  • Asia Pacific is projected to witness the fastest CAGR during the forecast period due to rapid adoption of cell-based approaches in healthcare and emergence of key players
  • Key players operating in the regenerative medicine market including AstraZeneca; F Hoffmann-La Roche Ltd.; Pfizer Inc.; Merck & Co., Inc.; Integra LifeSciences Corporation; and Eli Lilly and Company

Table of Contents

Chapter 1 Research Methodology

  • 1.1 Market Segmentation & Scope
  • 1.2 Market Definition
  • 1.3 Information Procurement
    • 1.3.1 Purchased database
    • 1.3.2 GVR's internal database
    • 1.3.3 Secondary sources & third party perspectives
    • 1.3.4 Primary research
  • 1.4 Information Analysis
    • 1.4.1 Data analysis models
  • 1.5 Market Formulation & Data Visualization
  • 1.6 Data Validation & Publishing

Chapter 2 Executive Summary

  • 2.1 Regenerative Medicine Market Outlook, 2014 - 2025
  • 2.2 Regenerative Medicine Market : Segment Outlook, 2014 - 2025
  • 2.3 Regenerative Medicine Market : Competitive Insights

Chapter 3 Regenerative Medicine Market Variables, Trends & Scope

  • 3.1 Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2 Penetration & Growth Prospect Mapping for Therapeutic Category, 2018
  • 3.3 Regenerative Medicine: Pipeline Analysis
    • 3.3.1 Astellas Pharma Inc.
    • 3.3.2 Bayer AG
    • 3.3.3 AstraZeneca
    • 3.3.4 F. Hoffmann-La Roche Ltd
    • 3.3.5 Pfizer Inc.
    • 3.3.6 Merck & Co., Inc.
    • 3.3.7 Abbott (St. Jude Children's Research Hospital)
    • 3.3.8 Vericel Corporation
    • 3.3.9 Novartis AG
    • 3.3.10 GlaxoSmithKline plc.
    • 3.3.11 Baxter
    • 3.3.12 Boehringer Ingelheim GmbH
    • 3.3.13 Amgen Inc.
    • 3.3.14 Eli Lilly and Company
    • 3.3.15 Bristol-Myers Squibb Company
    • 3.3.16 TAKARA BIO INC.
    • 3.3.17 Vital Therapies, Inc. (VTL)
    • 3.3.18 Swedish Orphan Biovitrum
    • 3.3.19 Stratatech Corporation
    • 3.3.20 Stempeutics Research Pvt. Ltd
    • 3.3.21 Soluble Systems, LLC
    • 3.3.22 Smith & Nephew plc
    • 3.3.23 Shire Pharmaceuticals Group PLC
    • 3.3.24 Beike Biotechnology Co., Ltd.
    • 3.3.25 SanBio, Inc.
    • 3.3.26 ReNeuron Group plc
    • 3.3.27 Regeneus Ltd.
    • 3.3.28 Regen BioPharma, Inc
    • 3.3.29 Q Therapeutics, Inc.
    • 3.3.30 Promethera Biosciences
    • 3.3.31 Pluristem Therapeutics, Inc. (PSTI)
    • 3.3.32 Pharmicell Co., Ltd.
    • 3.3.33 Osiris Therapeutics, Inc.
    • 3.3.34 Orthofix International NV
    • 3.3.35 Orthocell Limited
    • 3.3.36 Takeda Pharmaceutical Company Limited
    • 3.3.37 Caladrius
    • 3.3.38 U.S. Stem cell Inc.
    • 3.3.39 Cesca Therapeutics
    • 3.3.40 Osiris Therapeutics Inc.
    • 3.3.41 Astellas
    • 3.3.42 Opex Therapeutics, Inc.
    • 3.3.43 Northern Therapeutics, Inc.
    • 3.3.44 Northern Therapeutics, Inc.
    • 3.3.45 Neuralstem Inc.
    • 3.3.46 Multigene Vascular Systems, Inc.
    • 3.3.47 MEDIPOST Co.Ltd.
    • 3.3.48 Mesoblast Ltd.
    • 3.3.49 MacroCure, Inc.
    • 3.3.50 Living Cell Technologies, Ltd.
  • 3.4 Cost Structure Analysis
  • 3.5 User Perspective Analysis
    • 3.5.1. Consumer behavior analysis
    • 3.5.2. Market influencer analysis
  • 3.6 Technology Overview
  • 3.7 Regulatory Framework
    • 3.7.1 Regulatory environment: U.S.
    • 3.7.2 Regulatory environment: Canada
    • 3.7.3 Regulatory environment: Europe
    • 3.7.4 Regulatory environment: Japan
      • 3.7.4.1 Regenerative Medicine: Risk classification technique
    • 3.7.5 Regulatory environment: China
    • 3.7.6 Reimbursement framework
  • 3.8 Regenerative Medicine Market - Market Dynamics
    • 3.8.1 Market driver analysis
      • 3.8.1.1 Presence of strong pipeline portfolio and high number of clinical trials
      • 3.8.1.1.1 Major milestones & key events in regenerative medicine
      • 3.8.1.2 High economic impact of regenerative medicine
      • 3.8.1.3 Emerging applications of gene therapy in regenerative medicine
      • 3.8.1.4 Government & private funding to support the development of regenerative medicine (High investment & funding to support development of RM)
      • 3.8.1.5 Technological advances in regenerative medicine (stem cell, tissue engineering, and nanotechnology)
      • 3.8.1.6 Presence of strategic partnerships to accelerate development & commercialization of regenerative medicine
      • 3.8.1.7 Rising prevalence of chronic diseases & genetic disorders, degenerative diseases, and bone & joint diseases leading to rise in demand for regenerative treatments
    • 3.8.2 Market restraint analysis
      • 3.8.2.1 High cost of treatment
      • 3.8.2.2 Regulatory issues pertaining stem cell, tissues engineering and regenerative medicine
    • 3.8.3 Market challenges analysis
      • 3.8.3.3 Ethical issues related to use of stem cell & regenerative medicines for R&D
  • 3.9 Regenerative Medicine Market Analysis Tools
    • 3.9.1 Industry Analysis - Porter's
      • 3.9.1.1 Supplier power : High supplier bargaining power owing rising number of cord blood banks
      • 3.9.1.2 Buyer power: Moderate buyer bargaing power due to presence of strong pipeline of products
      • 3.9.1.3 Substitution threat: Presence of synthetic scaffolds and stents results in moderate substitution threat
      • 3.9.1.4 New entrants threat: Moderate threat of new entrants due to requirement of high capital
      • 3.9.1.5 Competitive rivalry: High competitive rivalry due to adoption of various strategies by the key players
    • 3.9.2 PESTEL analysis
      • 3.9.2.1 Political landscape
      • 3.9.2.2 Environmental landscape
      • 3.9.2.3 Social landscape
      • 3.9.2.4 Technology landscape
      • 3.9.2.5 Legal landscape
    • 3.9.3 Major deals & strategic alliances analysis
      • 3.9.3.1 Joint ventures
      • 3.9.3.2 Mergers & acquisitions
      • 3.9.3.3 Licensing & partnership
      • 3.9.3.4 Technology collaborations
      • 3.9.3.5 Strategic divestments
    • 3.9.4 Market entry strategies
    • 3.9.5 Case studies

Chapter 4 Regenerative Medicine Market: Competitive Analysis

  • 4.1 Recent Developments & Impact Analysis, by Key Market Participants
  • 4.2 Company/Competition Categorization
  • 4.3 Vendor Landscape
    • 4.3.1 List of key distributors and channel partners
    • 4.3.2 Key customers
    • 4.3.3 Key company market share analysis/ position analysis, 2018
  • 4.4 Public Companies
    • 4.4.1 Company market position analysis
    • 4.4.2 Company market share/ranking by region
    • 4.4.3 Competitive dashboard analysis
    • 4.4.4 Market differentiators
    • 4.4.5 Synergy analysis: Major deals & strategic alliances
  • 4.5 Private Companies
    • 4.5.1 List of key emerging companies
    • 4.5.2 Funding outlook
    • 4.5.3 Regional network map
    • 4.5.4 Company market position analysis
    • 4.5.5 List of supplier

Chapter 5 Regenerative Medicine Market Categorization: Product Type Estimates & Trend Analysis

  • 5.1. Definitions & Scope
  • 5.2. Product Type Market Share Analysis, 2018 & 2025
  • 5.3 Regenerative Medicine Market: Product Type Movement Analysis, 2018 & 2025
  • 5.4. Global Regenerative Medicine Market, by Product Type, 2014 to 2025
  • 5.5 Market Size & Forecasts and Trend Analyses, 2014 to 2025 for the following,
  • 5.6 Therapeutics
    • 5.6.1 Global regenerative medicine therapeutics market, 2014 - 2025 (USD Million)
    • 5.6.2 Primary cell-based therapeutics
      • 5.6.2.1 Global primary cell-bases therapeutics market, 2014 - 2025 (USD Million)
      • 5.6.2.2 Dermatology
      • 5.6.2.2.1 Various approaches for skin regeneration
      • 5.6.2.2.2 Global dermatology primary cell-bases therapeutics market, 2014 - 2025 (USD Million)
      • 5.6.2.3 Musculoskeletal
      • 5.6.2.3.1 Global musculoskeletal primary cell-bases therapeutics market, 2014 - 2025 (USD Million)
      • 5.6.2.4 Surgical
      • 5.6.2.4.1 Global surgical primary cell-bases therapeutics market, 2014 - 2025 (USD Million)
      • 5.6.2.5 Dental
      • 5.6.2.5.1 Global dental primary cell-bases therapeutics market, 2014 - 2025 (USD Million)
      • 5.6.2.6 Others
      • 5.6.2.6.1 Global other primary cell-bases therapeutics market, 2014 - 2025 (USD Million)
    • 5.6.3 Stem cell & progenitor cell-based therapeutics
      • 5.6.3.1 Global stem cell & progenitor cell-based therapeutics market, 2014 - 2025 (USD Million)
      • 5.6.3.2 Autologous
      • 5.6.3.2.1 Global autologous stem cell & progenitor cell-based therapeutics market, 2014 - 2025 (USD Million)
      • 5.6.3.3 Allogeneic
      • 5.6.3.3.1 Global allogeneic stem cell & progenitor cell-based therapeutics market, 2014 - 2025 (USD Million)
      • 5.6.3.4 Others
      • 5.6.3.4.1 Global other stem cell & progenitor cell-based therapeutics market, 2014 - 2025 (USD Million)
    • 5.6.4 Cell-based Immunotherapies
      • 5.6.4.1 Global cell-based immunotherapies market, 2014 - 2025 (USD Million)
    • 5.6.5 Gene Therapies
      • 5.6.5.1 Global gene therapies market, 2014 - 2025 (USD Million)
  • 5.7 Tools
    • 5.7.1 Global regenerative medicines tools market, 2014 - 2025 (USD Million)
    • 5.7.2 Laboratory equipment
      • 5.7.2.1 Global regenerative medicines laboratory equipment market, 2014 - 2025 (USD Million)
    • 5.7.3 Reagents & other consumables
      • 5.7.3.1 Global regenerative medicines reagents & other consumbales market, 2014 - 2025 (USD Million)
  • 5.8 Banks
    • 5.8.1 Global cell banks market, 2014 - 2025 (USD Million)
  • 5.9 Services
    • 5.9.1 Global regenerative medicine services market, 2014 - 2025 (USD Million)
  • 5.10 Regenerative Medicine Product Type Market, byTherapeutic Category, 2014 to 2025

Chapter 6 Regenerative Medicine Market Categorization: Therapeutic Category Estimates & Trend Analysis

  • 6.1. Definitions & Scope
  • 6.2. Therapeutic Category Market Share Analysis, 2018 & 2025
  • 6.3 Regenerative Medicine Market: Therapeutic Category Movement Analysis, 2018 & 2025
  • 6.4. Global Regenerative Medicine Market, by Therapeutic Category, 2014 to 2025
  • 6.5 Market Size & Forecasts and Trend Analyses, 2014 to 2025 for the following,
  • 6.6 Dermatology
    • 6.6.1 Global dermatological therapeutics market, 2014 - 2025 (USD Million)
  • 6.7 Musculoskeletal
    • 6.7.1 Global musculoskeletal therapeutics market, 2014 - 2025 (USD Million)
  • 6.8 Immunology & Inflammation
    • 6.8.1 Global immunology & inflammation therapeutics market, 2014 - 2025 (USD Million)
  • 6.9 Oncology
    • 6.9.1 Global oncology therapeutics market, 2014 - 2025 (USD Million)
  • 6.10 Cardiovascular
    • 6.10.1 Global cardiovascular therapeutics market, 2014 - 2025 (USD Million)
  • 6.11 Ophthalmology
    • 6.11.1 Global ophthalmology therapeutics market, 2014 - 2025 (USD Million)
  • 6.12 Others
    • 6.12.1 Global other therapeutics market, 2014 - 2025 (USD Million)

Chapter 7 Regenerative Medicine Market Categorization: Regional Estimates & Trend Analysis, by Product And Therapeutic Category

  • 7.1 Regenerative Medicine Market Share by Region, 2018 & 2025
  • 7.2 Regional Market Share and Leading Players, 2018
    • 7.2.1 North America
    • 7.2.2 Europe
    • 7.2.3 Asia Pacific
    • 7.2.4 Latin America
    • 7.2.5 Middle East & Africa
  • 7.3 North America
    • 7.3.1 North America regenerative medicines market, 2014 - 2025 (USD Million)
    • 7.3.2 U.S.
      • 7.3.2.1 U.S. regenerative medicine market, by product type, 2014 - 2025 (USD Million)
      • 7.3.2.2 U.S. regenerative medicine market, by therapeutic category, 2014 - 2025 (USD Million)
    • 7.3.3 Canada
      • 7.3.3.1 Canada regenerative medicines market, by product type 2014 - 2025 (USD Million)
      • 7.3.2.2 Canada regenerative medicine market, by therapeutic category, 2014 - 2025 (USD Million)
  • 7.4 Europe
    • 7.4.1 Europe regenerative medicines market, 2014 - 2025 (USD Million)
    • 7.4.2 Germany
      • 7.4.2.1 Germany regenerative medicines market, by product type 2014 - 2025 (USD Million)
      • 7.4.2.2 Germany regenerative medicines market, by therapeutic category 2014 - 2025 (USD Million)
    • 7.4.3 UK
      • 7.4.3.1 U.K. regenerative medicines market, 2014 - 2025 (USD Million)
      • 7.4.2.2 U.K. regenerative medicines market, by therapeutic category 2014 - 2025 (USD Million)
  • 7.5 Asia Pacific
    • 7.5.1 Asia Pacific regenerative medicines market, 2014 - 2025 (USD Million)
    • 7.5.2 Japan
      • 7.5.2.1 Japan regenerative medicines market, by product type 2014 - 2025 (USD Million)
      • 7.5.2.2 Japan regenerative medicines market, by therapeutic category 2014 - 2025 (USD Million)
    • 7.5.3 China
      • 7.5.3.1 China regenerative medicines market, by product type 2014 - 2025 (USD Million)
      • 7.5.2.2 China regenerative medicines market, by therapeutic category 2014 - 2025 (USD Million)
  • 7.6 Latin America
    • 7.6.1 Latin America regenerative medicines market, 2014 - 2025 (USD Million)
    • 7.6.2 Brazil
      • 7.6.2.1 Brazil regenerative medicines market, by product type 2014 - 2025 (USD Million)
      • 7.6.2.2 Brazil regenerative medicines market, by therapeutic category 2014 - 2025 (USD Million)
  • 7.7 Middle East & Africa (MEA)
    • 7.7.1 Middle East & Africa regenerative medicines market, 2014 - 2025 (USD Million)
    • 7.7.2 South Africa
      • 7.7.2.1 South Africa regenerative medicines market, by product type 2014 - 2025 (USD Million)
      • 7.7.2.2 South Africa regenerative medicines market, by therapeutic category 2014 - 2025 (USD Million)

Chapter 8 Competitive Landscape

  • 8.1 Strategy Framework
  • 8.2 Market Participation Categorization
  • 8.3 Company Profiles
    • 8.3.1 Integra LifeSciences Corporation
      • 8.3.1.1 Company overview
      • 8.3.1.2 Financial performance
      • 8.3.1.3 Product benchmarking
      • 8.3.1.4 Strategic initiatives
    • 8.3.2 Astellas Pharma Inc.
      • 8.3.2.1 Company overview
      • 8.3.2.1.1 Ocata Therapeutics, Inc.
      • 8.3.2.2 Financial performance
      • 8.3.2.2.1 Financial Performance
      • 8.3.2.3 Product benchmarking
      • 8.3.2.4 Strategic initiatives
    • 8.3.3 Corline Biomedical AB
      • 8.3.3.1 Company overview
      • 8.3.3.2 Financial performance
      • 8.3.3.3 Product benchmarking
      • 8.3.3.4 Strategic initiatives
    • 8.3.4 COOK BIOTECH, INC.
      • 8.3.4.1 Company overview
      • 8.3.4.2 Financial performance
      • 8.3.4.3 Product benchmarking
      • 8.3.4.4 Strategic initiatives
    • 8.3.5 Bayer BV
      • 8.3.5.1 Company overview
      • 8.3.5.1.1 BlueRock Therapeutics
      • 8.3.5.2 Financial performance
      • 8.3.5.3 Product benchmarking
      • 8.3.5.4 Strategic initiatives
    • 8.3.6 AstraZeneca
      • 8.3.6.1 Company overview
      • 8.3.6.1.1 MedImmune
      • 8.3.6.2 Financial performance
      • 8.3.6.3 Product benchmarking
      • 8.3.6.4 Strategic initiatives
    • 8.3.7 F. Hoffmann-La Roche Ltd
      • 8.3.7.1 Company overview
      • 8.3.7.2 Financial performance
      • 8.3.7.3 Product benchmarking
      • 8.3.7.4 Strategic initiatives
    • 8.3.8 Pfizer Inc.
      • 8.3.8.1 Company overview
      • 8.3.8.2 Financial performance
      • 8.3.8.3 Product benchmarking
      • 8.3.8.4 Strategic initiatives
    • 8.3.9 Merck & Co., Inc.
      • 8.3.9.1 Company overview
      • 8.3.9.1.1 Sigma-Aldrich Co. LLC
      • 8.3.9.1.2 Merck Millipore
      • 8.3.9.2 Financial performance
      • 8.3.9.2.1 Financial performance
      • 8.3.9.3 Product benchmarking
      • 8.3.9.4 Strategic initiatives
    • 8.3.10 Abbott
      • 8.3.10.1 Company overview
      • 8.3.10.1.1 St. Jude Medical, Inc.
      • 8.3.10.2 Financial performance
      • 8.3.10.2.1 Financial performance
      • 8.3.10.3 Product benchmarking
    • 8.3.11 Vericel Corporation
      • 8.3.11.1 Company overview
      • 8.3.11.2 Financial performance
      • 8.3.11.3 Product benchmarking
      • 8.3.11.4 Strategic initiatives
    • 8.3.12 Novartis AG
      • 8.3.12.1 Company overview
      • 8.3.12.1.1 Alcon
      • 8.3.12.2 Financial performance
      • 8.3.12.3 Product benchmarking
      • 8.3.12.4 Strategic initiatives
    • 8.3.13 GlaxoSmithKline plc.
      • 8.3.13.1 Company overview
      • 8.3.13.2 Financial performance
      • 8.3.13.3 Product benchmarking
      • 8.3.13.4 Strategic initiatives
    • 8.3.14 Baxter.
      • 8.3.14.1 Company overview
      • 8.3.14.1.1 Synovis Micro Companies Alliance Inc
      • 8.3.14.2 Financial performance
      • 8.3.14.3 Product benchmarking
    • 8.3.15 Boehringer Ingelheim GmbH(C.H.Boehringer Sohn AG & Co.KG, Ingelheim)
      • 8.3.15.1 Company overview
      • 8.3.15.2 Financial performance
      • 8.3.15.3 Product benchmarking
      • 8.3.15.4 Strategic initiatives
    • 8.3.16 Amgen Inc.
      • 8.3.16.1 Company overview
      • 8.3.16.2 Financial performance
      • 8.3.16.3 Product benchmarking
      • 8.3.16.4 Strategic initiatives
    • 8.3.17 Eli Lilly and Company
      • 8.3.17.1 Company overview
      • 8.3.17.2 Financial performance
      • 8.3.17.3 Product benchmarking
      • 8.3.17.4 Strategic initiatives
    • 8.3.18 Bristol-Myers Squibb Company
      • 8.3.18.1 Company overview
      • 8.3.18.1.1 iPierian, Inc
      • 8.3.18.2 Financial performance
      • 8.3.18.3 Product benchmarking
      • 8.3.18.4 Strategic initiatives
    • 8.3.19 Nuvasive, Inc.
      • 8.3.19.1 Company overview
      • 8.3.19.2 Financial performance
      • 8.3.19.3 Product benchmarking
      • 8.3.19.4 Strategic initiatives
    • 8.3.20 Organogenesis, Inc.
      • 8.3.20.1 Company overview
      • 8.3.20.1.1 NuTech
      • 8.3.20.2 Financial performance
      • 8.3.20.2.1 Financial performance
      • 8.3.20.3 Product benchmarking
      • 8.3.20.4 Strategic initiatives
    • 8.3.21 MiMedx Group, Inc.
      • 8.3.21.1 Company overview
      • 8.3.21.1.1 Stability, LLC.
      • 8.3.21.2 Financial performance
      • 8.3.21.3 Product benchmarking
      • 8.3.21.4 Strategic initiatives
    • 8.3.22 TAKARA BIO INC.
      • 8.3.22.1 Company overview
      • 8.3.22.2 Financial performance
      • 8.3.22.3 Product benchmarking
      • 8.3.22.4 Strategic initiatives
    • 8.3.23 Caladrius Biosciences, Inc.
      • 8.3.23.1 Company overview
      • 8.3.23.2 Financial performance
      • 8.3.23.3 Product benchmarking
      • 8.3.23.4 Strategic initiatives
    • 8.3.24 U.S. Stem Cell, Inc.
      • 8.3.24.1 Company overview
      • 8.3.24.2 Financial performance
      • 8.3.24.3 Product benchmarking
      • 8.3.24.4 Strategic initiatives
    • 8.3.25 Cesca Therapeutics
      • 8.3.25.1 Company overview
      • 8.3.25.2 Financial performance
      • 8.3.25.3 Product benchmarking
      • 8.3.25.4 Strategic initiatives
    • 8.3.26 Osiris Therapeutics, Inc
      • 8.3.26.1 Company overview
      • 8.3.26.2 Financial performance
      • 8.3.26.3 Product benchmarking
      • 8.3.26.4 Strategic initiatives
  • 8.4 List of Companies

List of Tables

  • TABLE 1 U.S.: Estimated costs involved in disease area and their associated cell- and gene-based therapies
  • TABLE 2 Global landscape: Number of regenerative medicine companies including cell therapeutic companies
  • TABLE 3 2016: Clinical trials in industry by technology type
  • TABLE 4 Tax incentives for life science R&D in leading countries
  • TABLE 5 Deaths attributable to neurological disorders as percentage of total deaths
  • TABLE 6 Estimated prevalence and number of people with diabetes (adult 18+ years)
  • TABLE 7 Global cancer incidences, 2017
  • TABLE 8 Summary of cystic fibrosis foundation patient registry (2014 & 2015)
  • TABLE 9 Regulatory status of cell-based tissue engineering & regenerative medicine
  • TABLE 10 FDA stratification of somatic cell therapy products based on intended use and extent of manipulation
  • TABLE 11 Collaborative networks and infrastructures that support regenerative medicine in Canada
  • TABLE 12 State Food and Drug Administration (SFDA) approved stem cell products
  • TABLE 13 Stem cell research institutes in China
  • TABLE 14 SFDA approved tissue-engineering products
  • TABLE 15 Regenerative medicine used in patients
  • TABLE 16 Various approaches in regenerative medicine for dermatological use
  • TABLE 17 Various types of scaffolds in in vitro study
  • TABLE 18 Predicted prevalence of Osteoporosis and Low Bone Mass for 2010 & 2030
  • TABLE 19 Prevalence of ophthalmic diseases in U.S
  • TABLE 20 Global burden of neurological diseases: Projected number of Disability Adjusted Life Years (DALYs) for neurological disorders
  • TABLE 21 North America: Clinical studies using HCT for hematopoietic and non-hematopoietic conditions (2016)
  • TABLE 22 North America regenerative medicines market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 23 North America regenerative therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 24 North America primary cell-bases therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 25 North America stem cell & progenitor cell-based therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 26 North America regeneratve medidince tools market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 27 North America regenerative medicine market estimates& forecasts, by therapeutic category, 2014 - 2025 (USD Million)
  • TABLE 28 U.S. regenerative medicines market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 29 U.S. regenerative therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 30 U.S. primary cell-bases therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 31 U.S. stem cell & progenitor cell-based therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 32 U.S. regeneratve medidince tools market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 33 U.S. regenerative medicine market estimates& forecasts, by therapeutic category, 2014 - 2025 (USD Million)
  • TABLE 34 Projected economic output of Canada's stem cell industry between 2015 and 2025
  • TABLE 35 Canada regenerative medicines market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 36 Canada regenerative therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 37 Canada primary cell-bases therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 38 Canada stem cell & progenitor cell-based therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 39 Canada regeneratve medidince tools market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 40 Canada regenerative medicine market estimates& forecasts, by therapeutic category, 2014 - 2025 (USD Million)
  • TABLE 41 Europe regenerative medicines market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 42 Europe regenerative therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 43 Europe primary cell-bases therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 44 Europe stem cell & progenitor cell-based therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 45 Europe regeneratve medidince tools market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 46 Europe regenerative medicine market estimates& forecasts, by therapeutic category, 2014 - 2025 (USD Million)
  • TABLE 47 Germany regenerative medicines market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 48 Germany regenerative therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 49 Germany primary cell-bases therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 50 Germany stem cell & progenitor cell-based therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 51 Germany regeneratve medidince tools market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 52 Germany regenerative medicine market estimates& forecasts, by therapeutic category, 2014 - 2025 (USD Million)
  • TABLE 53 U.K.: National action in regenerative medicine
  • TABLE 54 U.K.: Funds for regenerative medicine research: 2012-2017 (in USD million)
  • TABLE 55 U.K. regenerative medicines market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 56 U.K. regenerative therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 57 U.K. primary cell-bases therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 58 U.K. stem cell & progenitor cell-based therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 59 U.K. regeneratve medidince tools market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 60 U.K. regenerative medicine market estimates& forecasts, by therapeutic category, 2014 - 2025 (USD Million)
  • TABLE 61 Asia Pacific regenerative medicines market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 62 Asia Pacific regenerative therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 63 Asia Pacific primary cell-bases therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 64 Asia Pacific stem cell & progenitor cell-based therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 65 Asia Pacific regeneratve medidince tools market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 66 Asia Pacific regenerative medicine market estimates& forecasts, by therapeutic category, 2014 - 2025 (USD Million)
  • TABLE 67 Japan regenerative medicines market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 68 Japan regenerative therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 69 Japan primary cell-bases therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 70 Japan stem cell & progenitor cell-based therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 71 Japan regeneratve medidince tools market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 72 Japan regenerative medicine market estimates& forecasts, by therapeutic category, 2014 - 2025 (USD Million)
  • TABLE 73 Main monographs published in china
  • TABLE 74 China regenerative medicines market estimates& forecasts, by product, 2014 -2025 (USD Million)
  • TABLE 75 China regenerative therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 76 China primary cell-bases therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 77 China stem cell & progenitor cell-based therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 78 China regeneratve medidince tools market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 79 China regenerative medicine market estimates& forecasts, by therapeutic category, 2014 - 2025 (USD Million)
  • TABLE 80 Latin America: Current initiatives and opportunities
  • TABLE 81 Latin America regenerative medicines market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 82 Latin America regenerative therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 83 Latin America primary cell-bases therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 84 Latin America stem cell & progenitor cell-based therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 85 Latin America regeneratve medidince tools market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 86 Latin America regenerative medicine market estimates& forecasts, by therapeutic category, 2014 - 2025 (USD Million)
  • TABLE 87 Brazil regenerative medicines market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 88 Brazil regenerative therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 89 Brazil primary cell-bases therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 90 Brazil stem cell & progenitor cell-based therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 91 Brazil regeneratve medidince tools market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 92 Brazil regenerative medicine market estimates& forecasts, by therapeutic category, 2014 - 2025 (USD Million)
  • TABLE 93 Middle East & Africa regenerative medicines market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 94 Middle East & Africa regenerative therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 95 Middle East & Africa primary cell-bases therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 96 Middle East & Africa stem cell & progenitor cell-based therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 97 Middle East & Africa regeneratve medidince tools market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 98 Middle East & Africa regenerative medicine market estimates& forecasts, by therapeutic category, 2014 - 2025 (USD Million)
  • TABLE 99 South Africa regenerative medicines market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 100 South Africa regenerative therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 101 South Africa primary cell-bases therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 102 South Africa stem cell & progenitor cell-based therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 103 South Africa regeneratve medidince tools market estimates& forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 104 South Africa regenerative medicine market estimates& forecasts, by therapeutic category, 2014 - 2025 (USD Million)

List of Figures

  • FIG. 1 Market research process
  • FIG. 2 Information procurement
  • FIG. 3 Primary research pattern
  • FIG. 4 Market research approaches
  • FIG. 5 Value chain based sizing & forecasting
  • FIG. 6 QFD modelling for market share assessment
  • FIG. 7 Market summary
  • FIG. 8 Market trends & outlook
  • FIG. 9 Market segmentation & scope
  • FIG. 10 Market driver relevance analysis (Current & future impact)
  • FIG. 11 Shows the increased rate of clinical trials for Regenerative Medicines from 2014 to 2016.
  • FIG. 12 Trends in clinical trials in 2014, 2015, & 2016
  • FIG. 13 Investments in regenerative medicine in 2014, 2015, & 2016
  • FIG. 14 Shows the data on Prevalence of chronic diseases in U.S.
  • FIG. 15 Shows global data on deaths caused by diseases in 2015 (In Millions).
  • FIG. 16 Market restraint relevance analysis (Current & future impact)
  • FIG. 17 Penetration & growth prospect mapping for therapeutic category, 2018
  • FIG. 18 SWOT Analysis, By Factor (political & legal, economic and technological)
  • FIG. 19 Porter's Five Forces Analysis
  • FIG. 20 Regenerative Medicine: Risk classification technique
  • FIG. 21 Global regenerative medicine market: Product type outlook key takeaways
  • FIG. 22 Global regenerative medicine market: Product type movement analysis
  • FIG. 23 Global regenerative medicine therapeutics market, 2014 - 2025 (USD Million)
  • FIG. 24 Global primary cell-bases therapeutics market, 2014 - 2025 (USD Million)
  • FIG. 25 Various approaches for skin regeneration
  • FIG. 26 Global dermatology primary cell-bases therapeutics market, 2014 - 2025 (USD Million)
  • FIG. 27 Global musculoskeletal primary cell-bases therapeutics market, 2014 - 2025 (USD Million)
  • FIG. 28 Global surgical primary cell-bases therapeutics market, 2014 - 2025 (USD Million)
  • FIG. 29 Global dental primary cell-bases therapeutics market, 2014 - 2025 (USD Million)
  • FIG. 30 Global other primary cell-bases therapeutics market, 2014 - 2025 (USD Million)
  • FIG. 31 Global stem cell & progenitor cell-based therapeutics market, 2014 - 2025 (USD Million)
  • FIG. 32 Global autologous stem cell & progenitor cell-based therapeutics market, 2014 - 2025 (USD Million)
  • FIG. 33 Global allogeneic stem cell & progenitor cell-based therapeutics market, 2014 - 2025 (USD Million)
  • FIG. 34 Global other stem cell & progenitor cell-based therapeutics market, 2014 - 2025 (USD Million)
  • FIG. 35 Global cell-based immunotherapies market, 2014 - 2025 (USD Million)
  • FIG. 36 Global gene therapies market, 2014 - 2025 (USD Million)
  • FIG. 37 Global regenerative medicines tools market, 2014 - 2025 (USD Million)
  • FIG. 38 Global regenerative medicines laboratory equipmnet market, 2014 - 2025 (USD Million)
  • FIG. 39 Global regenerative medicines reagensts & other consumbales market, 2014 - 2025 (USD Million)
  • FIG. 40 Global cell banks market, 2014 - 2025 (USD Million)
  • FIG. 41 Global regenerative medicine services market, 2014 - 2025 (USD Million)
  • FIG. 42 Global regenerative medicine market: Therapeutic category outlook key takeaways
  • FIG. 43 Global regenerative medicine market: Therapeutic category movement analysis
  • FIG. 44 Global dermatological therapeutics category market, 2014 - 2025 (USD Million)
  • FIG. 45 Predicted prevalence of Osteoporosis and Low Bone Mass from 2010 to 2030
  • FIG. 46 Global musculoskeletal therapeutics category market, 2014 - 2025 (USD Million)
  • FIG. 47 Global immunology & inflammation therapeutics category market, 2014 - 2025 (USD Million)
  • FIG. 48 Global oncology therapeutics category market, 2014 - 2025 (USD Million)
  • FIG. 49 Global cardiovascular therapeutics category market, 2014 - 2025 (USD Million)
  • FIG. 50 Global ophthalmology therapeutics category market, 2014 - 2025 (USD Million)
  • FIG. 51 Global other therapeutics category market, 2014 - 2025 (USD Million)
  • FIG. 52 Regional market place: Key takeaway
  • FIG. 53 Regenerative medicine regional outlook, 2018 & 2025
  • FIG. 54 North America regenerative medicines market, 2014 - 2025 (USD Million)
  • FIG. 55 U.S regenerative medicines market, 2014 - 2025 (USD Million)
  • FIG. 56 Canada regenerative medicines market, 2014 - 2025 (USD Million)
  • FIG. 57 Europe regenerative medicines market, 2014 - 2025 (USD Million)
  • FIG. 58 Germany regenerative medicines market, 2014 - 2025 (USD Million)
  • FIG. 59 U.K. regenerative medicines market, 2014 - 2025 (USD Million)
  • FIG. 60 Asia Pacific regenerative medicines market, 2014 - 2025 (USD Million)
  • FIG. 61 Japan regenerative medicines market, 2014 - 2025 (USD Million)
  • FIG. 62 China regenerative medicines market, 2014 - 2025 (USD Million)
  • FIG. 63 Latin America regenerative medicines market, 2014 - 2025 (USD Million)
  • FIG. 64 Brazil regenerative medicines market, 2014 - 2025 (USD Million)
  • FIG. 65 Middle East & Africa regenerative medicines market, 2014 - 2025 (USD Million)
  • FIG. 66 South Africa regenerative medicines market, 2014 - 2025 (USD Million)
  • FIG. 67 Strategy framework
  • FIG. 68 Participant categorization
  • FIG. 69 List of companies
Back to Top